 Connection
Paul Bunn to Adenocarcinoma
This is a "connection" page, showing publications Paul Bunn has written about Adenocarcinoma.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.752 |
|
|
|
-
Bunn PA, Gaspar LE, Weyant MJ, Mitchell JD. Neoadjuvant combination chemotherapy for unresectable stage III non-small cell lung cancer. Cancer. 2016 Mar 01; 122(5):674-5.
Score: 0.306
-
Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014 May 21; 311(19):1998-2006.
Score: 0.274
-
Hirsch FR, Bunn PA. A new generation of EGFR tyrosine-kinase inhibitors in NSCLC. Lancet Oncol. 2012 May; 13(5):442-3.
Score: 0.236
-
Noonan SA, Patil T, Gao D, King GG, Thibault JR, Lu X, Bunn PA, Doebele RC, Purcell WT, Bar?n AE, Camidge DR. Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol. 2018 01; 13(1):134-138.
Score: 0.086
-
Pillai RN, Behera M, Berry LD, Rossi MR, Kris MG, Johnson BE, Bunn PA, Ramalingam SS, Khuri FR. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. Cancer. 2017 Nov 01; 123(21):4099-4105.
Score: 0.085
-
Steuer CE, Behera M, Berry L, Kim S, Rossi M, Sica G, Owonikoko TK, Johnson BE, Kris MG, Bunn PA, Khuri FR, Garon EB, Ramalingam SS. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. Cancer. 2016 Mar 01; 122(5):766-72.
Score: 0.077
-
Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015 May; 10(5):768-777.
Score: 0.073
-
Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, Ilouze M, Dvir A, Boyle T, Wynes M, Miller VA, Lipson D, Palmer GA, Ali SM, Dekel S, Brenner R, Bunn PA, Peled N. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist. 2015 Mar; 20(3):316-22.
Score: 0.072
-
Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Franklin WA, Camidge DR, Sequist LV, Haura EB, Ladanyi M, Kurland BF, Kugler K, Minna JD, Bunn PA, Kris MG. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer. 2015 Feb 01; 121(3):448-56.
Score: 0.070
-
Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA, Pao W. Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res. 2013 May 01; 19(9):2584-91.
Score: 0.063
-
Peled N, Hakim M, Bunn PA, Miller YE, Kennedy TC, Mattei J, Mitchell JD, Hirsch FR, Haick H. Non-invasive breath analysis of pulmonary nodules. J Thorac Oncol. 2012 Oct; 7(10):1528-33.
Score: 0.061
-
Bunn PA, Doebele RC. Genetic testing for lung cancer: reflex versus clinical selection. J Clin Oncol. 2011 May 20; 29(15):1943-5.
Score: 0.055
-
Byers T, Wolf HJ, Franklin WA, Braudrick S, Merrick DT, Shroyer KR, Hirsch FR, Zeng C, Bar?n AE, Bunn PA, Miller YE, Kennedy TC. Sputum cytologic atypia predicts incident lung cancer: defining latency and histologic specificity. Cancer Epidemiol Biomarkers Prev. 2008 Jan; 17(1):158-62.
Score: 0.044
-
Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA, Johnson GL, Hirsch FR, Merrick DT, Franklin WA, Baron AE, Keith RL, Nemenoff RA, Malkinson AM, Geraci MW. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol. 2005 Dec; 167(6):1763-75.
Score: 0.038
-
Kelly K, Mikhaeel-Kamel N, Pan Z, Murphy J, Prindiville S, Bunn PA. A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2000 Sep; 6(9):3474-9.
Score: 0.026
-
Bunn PA, Cohen MI, Widerlite L, Nugent JL, Matthews MJ, Minna JD. Simultaneous gastric and plasma immunoreactive plasma carcinoembryonic antigen in 108 patients undergoing gastroscopy. Gastroenterology. 1979 Apr; 76(4):734-41.
Score: 0.024
-
Bunn PA, Nugent JL, Ihde DC, Cohen MH, Eddy JL, Minna JD. 5-fluorouracil, methyl-CCNU, adriamycin, and mitomycin C in the treatment of advanced gastric cancer. Cancer Treat Rep. 1978 Sep; 62(9):1287-93.
Score: 0.023
-
Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, B?hm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA, Camidge DR, Tan AC, Hirsch FR, Heasley LE. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res. 2014 Jun 15; 20(12):3299-309.
Score: 0.017
-
Franklin WA, Waintrub M, Edwards D, Christensen K, Prendegrast P, Woods J, Bunn PA, Kolhouse JF. New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. Int J Cancer Suppl. 1994; 8:89-95.
Score: 0.017
-
Rafnar T, Sulem P, Besenbacher S, Gudbjartsson DF, Zanon C, Gudmundsson J, Stacey SN, Kostic JP, Thorgeirsson TE, Thorleifsson G, Bjarnason H, Skuladottir H, Gudbjartsson T, Isaksson HJ, Isla D, Murillo L, Garc?a-Prats MD, Panadero A, Aben KK, Vermeulen SH, van der Heijden HF, Feser WJ, Miller YE, Bunn PA, Kong A, Wolf HJ, Franklin WA, Mayordomo JI, Kiemeney LA, Jonsson S, Thorsteinsdottir U, Stefansson K. Genome-wide significant association between a sequence variant at 15q15.2 and lung cancer risk. Cancer Res. 2011 Feb 15; 71(4):1356-61.
Score: 0.014
-
Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, Rzyman W, Dziadziuszko K, Jassem J, Bunn PA, Varella-Garcia M, Hirsch FR. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol. 2010 May 01; 28(13):2174-80.
Score: 0.013
-
Pisters KM, Valli?res E, Crowley JJ, Franklin WA, Bunn PA, Ginsberg RJ, Putnam JB, Chansky K, Gandara D. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol. 2010 Apr 10; 28(11):1843-9.
Score: 0.013
-
Weiss GJ, Vokes EE, Bunn PA, Magree L, Rusk J, Albert D, Kelly K. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial. J Thorac Oncol. 2007 Oct; 2(10):933-8.
Score: 0.011
-
Seifter EJ, Bunn PA, Cohen MH, Makuch RW, Dunnick NR, Javadpour N, Bensimon H, Eddy JL, Minna JD, Ihde DC. A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate. J Clin Oncol. 1986 Sep; 4(9):1365-73.
Score: 0.010
-
Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA, Franklin WA, Crowley J, Gandara DR. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol. 2005 Oct 01; 23(28):6838-45.
Score: 0.009
-
Brower M, Carney DN, Ihde DC, Eddy J, Bunn PA, Cohen MH, Pelsor FR, Matthews MJ, Minna JD. High-dose methotrexate with leucovorin rescue in patients with unresectable non-small cell carcinoma of the lung. Cancer. 1983 Nov 15; 52(10):1778-82.
Score: 0.008
-
Krasnow S, Bunn PA, Ihde DC, Matthews MJ, Cohen MH, Eddy J, Minna JD. ICRF-159 in advanced gastric cancer. Absence of activity. Am J Clin Oncol. 1982 Dec; 5(6):635-9.
Score: 0.008
-
Carney DN, Gazdar AF, Bunn PA, Guccion JG. Demonstration of the stem cell nature of clonogenic tumor cells from lung cancer patients. Stem Cells (1981). 1982; 1(3):149-64.
Score: 0.007
-
Cohen AJ, Bunn PA, Franklin W, Magill-Solc C, Hartmann C, Helfrich B, Gilman L, Folkvord J, Helm K, Miller YE. Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux. Cancer Res. 1996 Feb 15; 56(4):831-9.
Score: 0.005
-
Lear JL, Kasliwal RK, Feyerabend AJ, Pratt JP, Bunn PA, Dienhart DG, Gonzalez R, Johnson TK, Bloedow DC, Maddock SW, et al. Improved tumor imaging with radiolabeled monoclonal antibodies by plasma clearance of unbound antibody with anti-antibody column. Radiology. 1991 May; 179(2):509-12.
Score: 0.003
-
Ihde DC, Cohen MH, Simms EB, Matthews MJ, Bunn PA, Minna JD. Evaluation of response to chemotherapy with fiberoptic bronchoscopy in non-small cell lung cancer. Cancer. 1980 Apr 01; 45(7):1693-6.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|